TCEANC2 and prostate carcinoma: Importantly, however, we identified several interesting chimeric transcripts including a promoter swap of TBL1XR1-PIK3CA that has previously been described in breast and prostate cancers,28 and additional fusions of WAPAL-CDHR1, MAP2K3-HMGCLL1, PARG-BMS1, FN1-ICAM1, AAK1-ARNT2, TNKS1BP1-SPARC, MBTPS1-TCEANC2, and PSMA6-SHMT1 (Figs. 5a–i and Supplementary Fig. 9).